Scientists are increasingly exploring the immune system as a potential target for treating depression and other mental disorders. A new line of research suggests that some psychiatric symptoms may arise not only from disruptions in brain neurotransmitters but also from changes in immune and inflammatory processes in the body. This concept underlies a new experimental therapy currently being prepared for clinical trials.

The article about this therapy was published in Molecular Psychiatry.

Traditional depression treatments mainly focus on modulating neurotransmitters such as serotonin and norepinephrine. However, a significant portion of patients—estimated at up to one-third—respond poorly to existing medications. This has prompted researchers to investigate alternative biological mechanisms underlying the disorder.

Increasing evidence indicates that some individuals with depression show signs of chronic inflammation and impaired immune regulation.

The new therapeutic strategy is based on the idea that immune signals can directly influence brain function. Certain immune molecules—such as cytokines—can alter neuronal activity, affecting mood, motivation, and energy levels. If these processes can be controlled, it could open a new avenue for treating depression, especially for patients who do not respond to standard antidepressants.

Researchers are currently developing an immunotherapeutic approach aimed at targeting inflammatory mechanisms linked to psychiatric symptoms. In upcoming clinical trials, they plan to test whether this therapy can reduce depression, anxiety, and other mental health symptoms. Some experts believe that if effective, this strategy could fundamentally change the way depression is treated.

At the same time, researchers emphasize that this therapy is still in the early stages of development. Clinical trials are needed to assess its safety, efficacy, and which patient groups may benefit most. Nevertheless, the growing understanding of the connection between the immune system and mental health may pave the way for entirely new treatments for psychiatric disorders in the future.